Premium
Y mAbs Therapeutics Inc (YMAB)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others. Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A...
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data...
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.05 | -13.125 | 8 | 8.34 | 6.89 | 242384 | 7.73966649 | CS |
| 4 | -2.85 | -29.0816326531 | 9.8 | 11.1 | 6.89 | 389591 | 8.27296903 | CS |
| 12 | -7.27 | -51.1251758087 | 14.22 | 16.11 | 6.89 | 295720 | 10.8272947 | CS |
| 26 | -4.34 | -38.4410983171 | 11.29 | 16.11 | 6.89 | 271193 | 12.01782852 | CS |
| 52 | -0.17 | -2.38764044944 | 7.12 | 20.9 | 6.89 | 328058 | 12.9539726 | CS |
| 156 | -6.59 | -48.670605613 | 13.54 | 20.9 | 2.7 | 415385 | 9.2801447 | CS |
| 260 | -24.96 | -78.2199937324 | 31.91 | 55.36 | 2.7 | 340629 | 16.06914022 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
